MX2022013398A - Compuestos de tetrahidroisoquinolina como activadores de nrf2. - Google Patents

Compuestos de tetrahidroisoquinolina como activadores de nrf2.

Info

Publication number
MX2022013398A
MX2022013398A MX2022013398A MX2022013398A MX2022013398A MX 2022013398 A MX2022013398 A MX 2022013398A MX 2022013398 A MX2022013398 A MX 2022013398A MX 2022013398 A MX2022013398 A MX 2022013398A MX 2022013398 A MX2022013398 A MX 2022013398A
Authority
MX
Mexico
Prior art keywords
compounds
nrf2 activators
tetrahydroisoquinoline compounds
nrf2
activators
Prior art date
Application number
MX2022013398A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas Charles Ray
George Hynd
Cathy Louise Lucas
Eileen Mary Seward
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of MX2022013398A publication Critical patent/MX2022013398A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022013398A 2020-04-22 2021-04-22 Compuestos de tetrahidroisoquinolina como activadores de nrf2. MX2022013398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005863.2A GB202005863D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds
PCT/GB2021/050973 WO2021214470A1 (en) 2020-04-22 2021-04-22 Tetrahydroisoquinoline compounds as nrf2 activators

Publications (1)

Publication Number Publication Date
MX2022013398A true MX2022013398A (es) 2022-12-13

Family

ID=70860156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013398A MX2022013398A (es) 2020-04-22 2021-04-22 Compuestos de tetrahidroisoquinolina como activadores de nrf2.

Country Status (16)

Country Link
US (1) US20230167084A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139294B1 (cg-RX-API-DMAC7.html)
JP (1) JP7679400B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004720A (cg-RX-API-DMAC7.html)
CN (1) CN115667243B (cg-RX-API-DMAC7.html)
AR (1) AR121912A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021259366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174361A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032247T3 (cg-RX-API-DMAC7.html)
GB (1) GB202005863D0 (cg-RX-API-DMAC7.html)
IL (1) IL297434A (cg-RX-API-DMAC7.html)
MX (1) MX2022013398A (cg-RX-API-DMAC7.html)
PH (1) PH12022552775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214470A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211465B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207469A (en) * 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds
CR20240325A (es) * 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
KR20180017038A (ko) * 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
MY207469A (en) 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds

Also Published As

Publication number Publication date
AR121912A1 (es) 2022-07-20
JP2023524206A (ja) 2023-06-09
EP4139294B1 (en) 2025-04-09
EP4139294A1 (en) 2023-03-01
JP7679400B2 (ja) 2025-05-19
CN115667243A (zh) 2023-01-31
KR20230004720A (ko) 2023-01-06
CA3174361A1 (en) 2021-10-28
US20230167084A1 (en) 2023-06-01
ZA202211465B (en) 2025-06-25
AU2021259366A1 (en) 2022-11-10
GB202005863D0 (en) 2020-06-03
WO2021214470A1 (en) 2021-10-28
PH12022552775A1 (en) 2024-03-25
BR112022021244A2 (pt) 2022-12-06
CN115667243B (zh) 2025-01-07
IL297434A (en) 2022-12-01
ES3032247T3 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
MX2021004566A (es) Compuestos terapeuticos.
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
CO2022016899A2 (es) Moduladores de il-17a
CO2022010241A2 (es) Inhibidores de sos1
CO2022018636A2 (es) Moduladores de il-17a
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
PY1909256A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2024001565A1 (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso.
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
UY35293A (es) Isotiazoles sustituidos con amino
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX383520B (es) Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
MX2019012522A (es) Compuestos y metodos terapeuticos.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
MX2022003398A (es) Composicion micelar inmunoestimulante.
MX2025009815A (es) Inhibidores de la integrina alfa4beta7 macrociclica
CL2021000282A1 (es) Inhibidores de ckd8/19
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators